Description: Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.
Home Page: eternatx.com
ERNA Technical Analysis
1035 Cambridge Street
Cambridge,
MA
02141
United States
Phone:
212 582 1199
Officers
| Name | Title |
|---|---|
| Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance |
| Mr. Sanjeev Luther | CEO, President & Director |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Ms. Dorothy J. Clarke | General Counsel & Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0975 |
| Price-to-Sales TTM: | 102.7176 |
| IPO Date: | 1992-10-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |